###begin article-title 0
Impact of Oxidative Stress and Peroxisome Proliferator-Activated Receptor gamma Coactivator-1alpha in Hepatic Insulin Resistance
###end article-title 0
###begin p 1
###xml 39 65 39 65 <email xmlns:xlink="http://www.w3.org/1999/xlink">hwatada@med.juntendo.ac.jp</email>
Corresponding author: Hirotaka Watada, hwatada@med.juntendo.ac.jp
###end p 1
###begin p 2
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See  for details.
###end p 2
###begin p 3
###xml 0 10 0 10 <bold xmlns:xlink="http://www.w3.org/1999/xlink">OBJECTIVE&#8212;</bold>
OBJECTIVE-Recent studies identified accumulation of reactive oxygen species (ROS) as a common pathway causing insulin resistance. However, whether and how the reduction of ROS levels improves insulin resistance remains to be elucidated. The present study was designed to define this mechanism.
###end p 3
###begin p 4
###xml 0 28 0 28 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESEARCH DESIGN AND METHODS&#8212;</bold>
###xml 138 143 138 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 145 149 <span type="species:ncbi:10090">mice</span>
RESEARCH DESIGN AND METHODS-We investigated the effect of overexpression of superoxide dismutase (SOD)1 in liver of obese diabetic model (db/db) mice by adenoviral injection.
###end p 4
###begin p 5
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESULTS&#8212;</bold>
###xml 8 13 8 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 84 89 84 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 648 649 632 633 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 731 736 715 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 14 18 <span type="species:ncbi:10090">mice</span>
###xml 90 94 <span type="species:ncbi:10090">mice</span>
###xml 737 741 <span type="species:ncbi:10090">mice</span>
RESULTS-db/db mice had high ROS levels in liver. Overexpression of SOD1 in liver of db/db mice reduced hepatic ROS and blood glucose level. These changes were accompanied by improvement in insulin resistance and reduction of hepatic gene expression of phosphoenol-pyruvate carboxykinase and peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha), which is the main regulator of gluconeogenic genes. The inhibition of hepatic insulin resistance was accompanied by attenuation of phosphorylation of cAMP-responsive element-binding protein (CREB), which is a main regulator of PGC-1alpha expression, and attenuation of Jun NH2-terminal kinase (JNK) phosphorylation. Simultaneously, overexpression of SOD1 in db/db mice enhanced the inactivation of forkhead box class O1, another regulator of PGC-1alpha expression, without the changes of insulin-induced Akt phosphorylation in liver. In hepatocyte cell lines, ROS induced phosphorylation of JNK and CREB, and the latter, together with PGC-1alpha expression, was inhibited by a JNK inhibitor.
###end p 5
###begin p 6
###xml 0 12 0 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CONCLUSIONS&#8212;</bold>
CONCLUSIONS-Our results indicate that the reduction of ROS is a potential therapeutic target of liver insulin resistance, at least partly by the reduced expression of PGC-1alpha.
###end p 6
###begin p 7
Published ahead of print at  on 16 May 2008.
###end p 7
###begin p 8
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 8
###begin p 9
###xml 597 598 597 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 599 600 599 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 766 767 766 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 768 769 768 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
Accumulation of reactive oxygen species (ROS) plays a critical role in the pathogenesis of various diseases. ROS are generated by the electron transport chain in mitochondrial respiration and are thus increased in conditions associated with enhanced oxidation of energy substrate such as glucose and free fatty acids. Furthermore, ROS is produced by NADPH oxidase, which is activated by various cytokines. The state of insulin resistance is accompanied by increases in the levels of blood glucose, free fatty acids, and adipocytokines and is thus regarded as a state of increased exposure to ROS (1,2). Although the exact mechanism of insulin resistance is not fully understood, recent data implicate ROS in the pathogenesis of multiple forms of insulin resistance (3-5). However, there is little or no information on how ROS induce insulin resistance in vivo.
###end p 9
###begin p 10
###xml 268 269 268 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 526 527 526 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
The tissue ROS level in each organ depends on the production and elimination of ROS. Superoxide dismutases (SODs) are major antioxidant enzymes that degrade superoxide into hydrogen peroxide. At present, three distinct isoforms of SOD have been identified in mammals (6). SOD1, or CuZn-SOD, is a copper- and zinc-containing homodimer. Although this enzyme had been regarded to be expressed exclusively in the cytoplasm, at least in rodent liver, it is found both in the intermembrane space of mitochondria and in the cytosol (7). SOD2, or Mn-SOD, is a manganese-containing enzyme found almost exclusively in the mitochondria. SOD3, or EC-SOD, is the most recently characterized SOD; it exists as a copper- and zinc-containing tetramer and contains a signal peptide that directs this enzyme exclusively to extracellular spaces.
###end p 10
###begin p 11
###xml 169 174 169 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 144 149 <span type="species:ncbi:9606">human</span>
###xml 175 179 <span type="species:ncbi:10090">mice</span>
The present study was designed to explore the effect of ROS on hepatic insulin resistance. For this purpose, we injected an adenovirus encoding human SOD1 (AdSOD1) into db/db mice, a genetic model of type 2 diabetes. The results demonstrated that reduction of ROS in liver improved glucose tolerance with reduced expression of gluconeogenic genes. The reduced expression of peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha), independent of insulin signaling at the Akt phosphorylation level, seems to be involved in this mechanism.
###end p 11
###begin title 12
RESEARCH DESIGN AND METHODS
###end title 12
###begin title 13
Recombinant adenoviral vectors.
###end title 13
###begin p 14
###xml 130 131 130 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 43 48 <span type="species:ncbi:9606">human</span>
###xml 317 322 <span type="species:ncbi:9606">human</span>
The recombinant adenovirus AdSOD1 encoding human SOD1 was kindly provided by Dr. David A. Brenner (University of North Carolina) (8). The control adenovirus encoding beta-galactosidase (AdLacZ) was kindly provided by Dr. Michael S. German (University of California San Francisco). Both adenoviruses were amplified in human embryonic kidney (HEK)-293 cells and purified by cesium chloride density centrifugation. Viral titers were determined by the method of tissue culture infective doses 50.
###end p 14
###begin title 15
Animals and administration of recombinant adenovirus.
###end title 15
###begin p 16
###xml 137 142 137 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 186 190 186 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/m</italic>
###xml 473 474 473 474 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
###xml 608 613 608 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 143 147 <span type="species:ncbi:10090">mice</span>
###xml 191 195 <span type="species:ncbi:10090">mice</span>
###xml 248 252 <span type="species:ncbi:10090">mice</span>
###xml 614 618 <span type="species:ncbi:10090">mice</span>
###xml 792 796 <span type="species:ncbi:10090">Mice</span>
The study was reviewed and approved by the animal care and use committee of Juntendo University. Specific-pathogen-free female C57BL/KsJ-db/db mice and their lean littermates, C57BL/KsJ-db/m mice, were purchased from Japan Clea (Tokyo, Japan). All mice were housed in stainless steel wire cages in a temperature-controlled clean room with a 12:12 h light-dark cycle. The animals were provided with standard diet and autoclaved tap water ad libitum. AdSOD1 or AdLacZ (5 x 107 plaque-forming units) diluted in PBS buffer or the same volume of PBS alone was injected through the tail vein of 12- to 18-week-old db/db mice, whose fasting blood glucose values had reached approximately180 mg/dl. Blood samples were collected from the tail vein to measure blood glucose and insulin concentrations. Mice were sacrificed under anesthesia induced by intraperitoneal injection of sodium pentobarbital (50 mg/kg) (Nembutal; Abbott Laboratories, Abbott Park, IL).
###end p 16
###begin title 17
Visualization of intracellular superoxide.
###end title 17
###begin p 18
###xml 149 150 149 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
The oxidation-dependent fluorescent dye dihydroethidium (DHE) (Sigma Chemical, St. Louis, MO) was used to evaluate in situ production of superoxide (9). Unfixed frozen livers were cut into 5-mum-thick sections, which were placed on glass slides. Twenty micromolars of DHE were applied to the surface of each tissue section, and the slides were incubated in a light-protected humid chamber at 37degreesC for 30 min. Images were obtained with a microscope (DXM1200; Nikon, Tokyo, Japan) equipped with a krypton/argon laser. Laser and power settings were identical during acquisition of images of various specimens. Fluorescence was detected with a 585-nm-long pass filter.
###end p 18
###begin title 19
Laboratory tests.
###end title 19
###begin p 20
Blood glucose concentrations were measured by a portable glucose meter using the One Touch Ultra (LifeScan, Milpitas, CA). Plasma insulin was measured using an insulin ELISA kit (Morinaga, Takamatsu, Japan).
###end p 20
###begin title 21
Nitrotyrosine assay.
###end title 21
###begin p 22
###xml 91 93 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
Nitrotyrosine was measured with a nitrotyrosine ELISA kit (OxisResearch, Foster City, CA) (10) using whole-cell extracts of each liver.
###end p 22
###begin title 23
Intraperitoneal glucose tolerance, insulin tolerance, and pyruvate challenge tests.
###end title 23
###begin p 24
###xml 242 244 242 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 38 42 <span type="species:ncbi:10090">mice</span>
At 5 days after adenovirus infection, mice were injected intraperitoneally with glucose (0.5 g/kg body wt), regular insulin (2 units/kg body wt) (Humulin; Eli Lilly, Indianapolis, IN), or pyruvate (1.5 g/kg body wt), as previously described (11); blood glucose and serum insulin levels were subsequently measured as described above.
###end p 24
###begin title 25
Immunoprecipitation assay and Western blot analysis.
###end title 25
###begin p 26
###xml 495 497 495 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 559 560 559 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 687 689 681 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 979 981 967 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 1232 1235 1216 1219 <sup xmlns:xlink="http://www.w3.org/1999/xlink">307</sup>
###xml 1492 1495 1472 1475 <sup xmlns:xlink="http://www.w3.org/1999/xlink">473</sup>
###xml 1591 1594 1571 1574 <sup xmlns:xlink="http://www.w3.org/1999/xlink">133</sup>
###xml 1694 1697 1674 1677 <sup xmlns:xlink="http://www.w3.org/1999/xlink">202</sup>
###xml 1701 1704 1681 1684 <sup xmlns:xlink="http://www.w3.org/1999/xlink">204</sup>
###xml 1738 1741 1718 1721 <sup xmlns:xlink="http://www.w3.org/1999/xlink">256</sup>
###xml 1793 1796 1773 1776 <sup xmlns:xlink="http://www.w3.org/1999/xlink">180</sup>
###xml 1800 1803 1780 1783 <sup xmlns:xlink="http://www.w3.org/1999/xlink">182</sup>
###xml 1903 1906 1883 1886 <sup xmlns:xlink="http://www.w3.org/1999/xlink">183</sup>
###xml 1911 1914 1891 1894 <sup xmlns:xlink="http://www.w3.org/1999/xlink">185</sup>
###xml 1985 1996 <span type="species:ncbi:3704">Horseradish</span>
###xml 2024 2030 <span type="species:ncbi:9986">rabbit</span>
###xml 2040 2045 <span type="species:ncbi:10090">mouse</span>
To determine the tissue distribution of SOD1 expression, various tissues were isolated at 7 days after infection with the adenovirus. To investigate the effect of adenovirus injection, after overnight fasting, the livers were isolated, weighed, and snap-frozen in liquid nitrogen. Some livers were collected at 5 min after injection of 0.5 units regular insulin through inferior vena cava. The isolated tissues were then homogenized by a handheld homogenizer in radioimmunoprotein assay buffer (12). The samples were sonicated on ice and centrifuged at 15,000g at 4degreesC for 30 min. The supernatants were collected and Western blotting analysis was performed as previously described (13). For the immunoprecipitation assay, the isolated tissues were homogenized in radioimmunoprotein assay buffer and immunoprecipitation was conducted by incubating supernatant containing the same amount of protein with the indicated antibody and protein G sepharose for 1 hour at 4degreesC (12). Anti-CuZn-SOD antibody, anti-PGC-1alpha antibody, and anti-forkhead transcription factor (FKHR) (H-128) antibody were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-insulin receptor substrate (IRS)-1 antibody, anti-phospho-IRS-1(Ser307) antibody, anti-IRS-2 antibody, anti-phosphotyrosine, clone 4G10 antibody, anti-phosphatidylinositol 3 (PI3)-kinase p85 antibody, and anti-Akt1/protein kinase B-alpha antibody were obtained from Upstate Biotechnology (Lake Placid, NY). Anti-phosphoAkt (Ser473) antibody, anti-cAMP-responsive element-binding protein (CREB) antibody, anti-phospho-CREB (Ser133) antibody, anti-p44/p42 (extracellular signal-related kinase [ERK]) antibody, anti-phospho-ERK (Thr202/Tyr204) antibody, anti-phospho-FKHR (Ser256) antibody, anti-p38 antibody, anti-phospho-p38 (Thr180/Tyr182) antibody, anti-stress-activated protein kinase (SAPK)/JNK antibody, and anti-phospho-SAPK/JNK (Thr183/Tyr 185) antibody were obtained from Cell Signaling Technology (Beverly, MA). Horseradish peroxidase-conjugated anti-rabbit and anti-mouse antibodies were purchased from Bio-Rad Laboratories (Tokyo, Japan).
###end p 26
###begin title 27
Isolation of tissue RNA and real-time quantitative RT-PCR.
###end title 27
###begin p 28
###xml 508 509 508 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 509 510 509 510 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T</sub>
###xml 738 740 734 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 605 610 <span type="species:ncbi:10090">mouse</span>
###xml 807 812 <span type="species:ncbi:10090">mouse</span>
###xml 884 889 <span type="species:ncbi:10090">mouse</span>
###xml 966 971 <span type="species:ncbi:9606">human</span>
###xml 1066 1071 <span type="species:ncbi:9606">human</span>
Total RNA was extracted from livers by using TRIzol reagent (Invitrogen, Carlsbad, CA). cDNAs were then synthesized using Superscript III RNase H Reverse Transcriptase (Invitrogen) and oligo-dT primers. The resulting cDNAs were amplified using SYBR Green PCR kit (Applied Biosystems, Foster City, CA). Quantitative PCR was performed on an ABI PRISM 7700 sequence detection system (Perkin Elmer Life Sciences, Boston, MA). The relative abundance of mRNAs was calculated by the comparative cycle of threshold (CT) method with TATA box-binding protein mRNA as the invariant control. The primer sequences for mouse PGC-1alpha, phosphoenol-pyruvate carboxykinase (PEPCK), glucose-6-phosphatase (G6Pase), and glucokinase were previously shown (11). The following primers were also used: TATA box-binding protein (mouse) forward CTCAGTTACAGGTGGCAGCA and reverse ACCAACAATCACCAACAGCA, IRS-2 (mouse) forward CAGCTATTGGGACCACCACT and reverse GTAGTTCAGGTCGCCTCTGC, PGC-1alpha (human) forward CCTGCATGAGTGTGTGCTCT and reverse GCAAAGAGGCTGGTCTTCAC, and TATA box-binding protein (human) forward CGGCTGTTTAACTTCGCTTC and reverse TTCTTGGCAAACCAGAAACC.
###end p 28
###begin title 29
Cell culture.
###end title 29
###begin p 30
###xml 296 297 289 290 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 683 685 674 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 686 688 677 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 799 800 789 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human Huh7 hepatocarcinoma cells were kindly provided by Dr. Kenichi Ikejima (Juntendo University, Tokyo). We cultured Huh7 cells in high-glucose Dulbecco's modified Eagle's medium supplemented with 10% FCS, 100 units/ml penicillin, and 100 mug/ml streptomycin at 37degreesC in a humidified 5% CO2 environment. To load ROS, Huh7 cells were grown to confluence on six-well plates, incubated overnight in serum-free low-glucose Dulbecco's modified Eagle's medium, and then treated with 400 mumol/l xanthine and 40 mU/ml xanthine oxidase (Sigma) for the indicated time. For analysis of the antioxidant effect, cells were treated with 400 mumol/l butylated hydroxyanisole (BHA) (Sigma) (14,15) or 400 mumol/l manganese (III) tetrakis (4-benzoicacid) porphyrin (MnTBAP) (A.G. Scientific, San Diego, CA) (3) 20 min before the addition of xanthine and xanthine oxidase load. After treatment for the indicated time, cells were washed with PBS and harvested with a scraper. Protein samples or RNA samples were prepared from the lysates and applied for Western blotting or real-time PCR, respectively. In some experiments, we used SP600125 (Calbiochem, San Diego, CA), which is a specific inhibitor of JNK.
###end p 30
###begin title 31
Statistical analysis.
###end title 31
###begin p 32
###xml 126 127 124 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 257 258 255 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Results are expressed as means +/- SD. Differences between two groups were analyzed for statistical significance by Student's t test for unpaired comparisons. Comparisons among more than two groups were assessed with ANOVA, followed by a Bonferroni test. A P value <0.05 was considered statistically significant.
###end p 32
###begin title 33
RESULTS
###end title 33
###begin title 34
###xml 40 45 40 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 46 50 <span type="species:ncbi:10090">mice</span>
AdSOD1 treatment reduces hepatic ROS in db/db mice.
###end title 34
###begin p 35
###xml 120 125 120 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 337 342 337 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 374 378 374 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/m</italic>
###xml 571 572 571 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 565 572 565 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 842 846 842 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/m</italic>
###xml 859 860 859 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 853 860 853 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 1047 1052 1047 1052 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 1078 1082 1078 1082 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/m</italic>
###xml 1114 1119 1114 1119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 1202 1206 1202 1206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/m</italic>
###xml 1246 1251 1246 1251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 1298 1299 1298 1299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1292 1299 1292 1299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>C</italic></xref>
###xml 1385 1390 1385 1390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 1431 1435 1431 1435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/m</italic>
###xml 126 130 <span type="species:ncbi:10090">mice</span>
###xml 343 347 <span type="species:ncbi:10090">mice</span>
###xml 379 383 <span type="species:ncbi:10090">mice</span>
###xml 473 478 <span type="species:ncbi:9606">human</span>
###xml 847 851 <span type="species:ncbi:10090">mice</span>
###xml 1053 1057 <span type="species:ncbi:10090">mice</span>
###xml 1083 1087 <span type="species:ncbi:10090">mice</span>
###xml 1120 1124 <span type="species:ncbi:10090">mice</span>
###xml 1207 1211 <span type="species:ncbi:10090">mice</span>
###xml 1252 1256 <span type="species:ncbi:10090">mice</span>
###xml 1391 1395 <span type="species:ncbi:10090">mice</span>
###xml 1436 1440 <span type="species:ncbi:10090">mice</span>
To investigate the effect of reduction of ROS in liver on insulin resistance, we overexpressed SOD1 protein in liver of db/db mice by tail-vein injection of AdSOD1, followed by determination of SOD1 gene expression in various organs. Although the expression level of endogenous SOD1 (estimated molecular weight 15.9 kDa) in the liver of db/db mice was not less than that in db/m mice, endogenous SOD1 was expressed in every organ investigated. On the other hand, exogenous human SOD1 (estimated molecular weight 19.0 kDa) was detected only in AdSOD1-treated liver (Fig. 1A). To investigate the effect of SOD1 expression on ROS level in the liver, we stained each liver with the oxidation-dependent fluorescent dye DHE. Hepatic overexpression of SOD1 was associated with reduced level of superoxide in liver to a level comparable with that in db/m mice (Fig. 1B). This effect was persistently observed from 1 to at least 7 days after the injection of AdSOD1 (data not shown). Nitrotyrosine, a representative marker of protein oxidation in liver of db/db mice, was higher than in db/m mice. Injection of AdSOD1 into db/db mice significantly reduced nitrotyrosine level to a level comparable with that in db/m mice, whereas injection of AdLacZ into db/db mice did not alter nitrotyrosine level (Fig. 1C). These results show that AdSOD1 treatment reduced the increased ROS in the liver of db/db mice to a level compatible with that of db/m mice.
###end p 35
###begin title 36
###xml 62 67 62 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 67 71 67 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mice</italic>
Hepatic expression of SOD1 ameliorates glucose intolerance in db/dbmice.
###end title 36
###begin p 37
###xml 164 169 164 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 194 195 194 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 188 195 188 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic></xref>
###xml 471 472 471 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 465 472 465 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>B</italic></xref>
###xml 897 898 897 898 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 903 904 903 904 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 891 904 891 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>C</italic> and <italic>D</italic></xref>
###xml 1043 1044 1043 1044 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1037 1044 1037 1044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>E</italic></xref>
###xml 1427 1428 1427 1428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1421 1428 1421 1428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>F</italic></xref>
###xml 170 174 <span type="species:ncbi:10090">mice</span>
###xml 392 396 <span type="species:ncbi:10090">mice</span>
###xml 429 433 <span type="species:ncbi:10090">mice</span>
###xml 459 463 <span type="species:ncbi:10090">mice</span>
###xml 544 548 <span type="species:ncbi:10090">mice</span>
###xml 608 612 <span type="species:ncbi:10090">mice</span>
###xml 690 694 <span type="species:ncbi:10090">mice</span>
###xml 975 979 <span type="species:ncbi:10090">mice</span>
###xml 1031 1035 <span type="species:ncbi:10090">mice</span>
###xml 1387 1391 <span type="species:ncbi:10090">mice</span>
###xml 1415 1419 <span type="species:ncbi:10090">mice</span>
To elucidate the effect of the reduction of hepatic ROS on glucose metabolism, we investigated the effect of SOD1 overexpression in liver on blood glucose level in db/db mice. As shown in Fig. 2A, treatment with AdSOD1 induced marked reduction of nonfasting blood glucose level from 2 days after AdSOD1 injection, and this effect continued for at least 33 days. Body weight of AdSOD1-treated mice was higher than that of AdLacZ- mice and PBS-injected control mice (Fig. 2B). We measured food intake in each group. Food intake of AdSOD1-treated mice was comparable with that of AdLacZ-treated and PBS-treated mice (data not shown). Accordingly, the increase in body weight in AdSOD1-treated mice was independent of food intake. Intraperitoneal glucose tolerance test revealed that AdSOD1 treatment ameliorated glucose tolerance without an increase in serum insulin level during glucose load (Fig. 2C and D). Intraperitoneal insulin tolerance test revealed that AdSOD1-treated mice had better insulin sensitivity than AdLacZ-treated mice (Fig. 2E). To confirm that the improvement of insulin resistance was mainly due to changes in hepatic glucose metabolism, we measured blood glucose levels after intraperitoneal injection of pyruvate, which is the main precursor of gluconeogenesis. The increase in blood glucose level after pyruvate injection was significantly lower in AdSOD1-treated mice than in AdLacZ-treated mice (Fig. 2F). These data indicate that hepatic overexpression of SOD1 improved glucose tolerance mainly by improvement of insulin sensitivity, thus reducing blood glucose level. The reduction of hepatic gluconeogenesis might be at least partly involved in the mechanism.
###end p 37
###begin p 38
###xml 246 251 246 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 252 256 <span type="species:ncbi:10090">mice</span>
Steatosis may partly play a causal role in obesity-induced insulin resistance. We investigated the effect of SOD1 expression on hepatic lipid accumulation by Oil Red O staining. The overexpression of SOD1 increased lipid accumulation in liver of db/db mice (data not shown). Thus, the improvement of insulin sensitivity in this model is independent of the change of steatosis.
###end p 38
###begin title 39
SOD1 expression in liver reduces PGC-1alpha expression.
###end title 39
###begin p 40
###xml 293 298 293 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PEPCK</italic>
###xml 394 400 394 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G6Pase</italic>
###xml 670 672 666 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 673 675 669 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 815 816 811 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink">3</italic>
###xml 810 816 806 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. <italic>3</italic></xref>
###xml 1011 1016 1003 1008 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 1017 1021 <span type="species:ncbi:10090">mice</span>
To investigate the mechanism of improvement of hepatic insulin sensitivity by overexpression of SOD1, we measured the mRNA expression of the main regulators of glucose metabolism in the liver by quantitative real-time PCR. Overexpression of SOD1 significantly reduced the expression levels of PEPCK, the rate-limiting enzyme of gluconeogenesis. It also modestly reduced the expression level of G6Pase, although the effect was not statistically significant. These changes in the expression of gluconeogenic genes were associated with a significant reduction of mRNA and protein-level PGC-1alpha, which is the main regulator of the expression of both gluconeogenic genes (16,17). On the other hand, overexpression of SOD1 did not alter the gene expression of glucokinase, the rate-limiting enzyme of glycolysis (Fig. 3). These data indicate that downregulation of PGC-1alpha, which is a main regulator of gluconeogenic genes, may play a key role in the improvement of glucose tolerance by the reduction of ROS in db/db mice.
###end p 40
###begin title 41
Overexpression of SOD1 increased the phosphorylation of Foxo1 independently of Akt phosphorylation level in the liver.
###end title 41
###begin p 42
###xml 146 148 142 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 255 260 251 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 520 521 516 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 514 521 510 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 813 814 809 810 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 807 814 803 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 1003 1004 999 1000 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 997 1004 993 1000 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 1218 1219 1214 1215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1212 1219 1208 1215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 1252 1255 1248 1251 <sup xmlns:xlink="http://www.w3.org/1999/xlink">307</sup>
###xml 1265 1266 1261 1262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 1267 1269 1263 1265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
###xml 1270 1272 1266 1268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
###xml 1416 1418 1412 1414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 1419 1421 1415 1417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 1519 1522 1515 1518 <sup xmlns:xlink="http://www.w3.org/1999/xlink">307</sup>
###xml 1550 1551 1546 1547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1544 1551 1540 1547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>B</italic></xref>
###xml 1588 1591 1584 1587 <sup xmlns:xlink="http://www.w3.org/1999/xlink">307</sup>
###xml 1767 1772 1763 1768 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 1846 1849 1842 1845 <sup xmlns:xlink="http://www.w3.org/1999/xlink">307</sup>
###xml 261 265 <span type="species:ncbi:10090">mice</span>
###xml 773 777 <span type="species:ncbi:10090">mice</span>
###xml 801 805 <span type="species:ncbi:10090">mice</span>
###xml 963 967 <span type="species:ncbi:10090">mice</span>
###xml 991 995 <span type="species:ncbi:10090">mice</span>
###xml 1773 1777 <span type="species:ncbi:10090">mice</span>
Insulin suppresses the expression of the PGC-1alpha gene at least partly through Akt-stimulated phosphorylation of forkhead box class O1 (Foxo1) (18). Thus, we investigated the insulin-signaling transduction pathway in liver of AdLacZ- and AdSOD1-treated db/db mice. Although IRS-1 and IRS-2 are both important molecules involved in insulin signaling, the expression of IRS-1 protein in AdSOD1 group was significantly higher, and the expression of IRS-2 protein significantly lower, than that in the AdLacZ group (Fig. 4A). We quantitatively confirmed the changes of the expression of these proteins (data not shown). Parallel to the respective expression level, insulin-stimulated tyrosine phosphorylation of IRS-1 was higher and that of IRS-2 was lower in AdSOD1-treated mice than in AdLacZ-treated mice (Fig. 4A). Reflecting these changes, the binding affinity to p85, a subunit of PI3 kinase of IRS-1, was higher and that of IRS-2 was lower in AdSOD1-treated mice than in AdLacZ-treated mice (Fig. 4A). Probably because the reduced IRS-2 phosphorylation can counteract the increased IRS-1 phosphorylation, insulin-stimulated phosphorylation of Akt might not be eventually affected by overexpression of SOD1 (Fig. 4A). IRS-1 is phosphorylated at Ser307 residue (5,19,20) by several cytokines; this modification reduces insulin-stimulated tyrosine phosphorylation of IRS-1 and stimulates the degradation of IRS-1 (21,22). Thus, we investigated the effect of reduction of ROS on the phosphorylation of IRS-1 at the Ser307 residue. As shown in Fig. 4B, phosphorylation of IRS-1 at the Ser307 residue was reduced by reduction of ROS. These findings indicate that the increase of insulin-stimulated tyrosine phosphorylation of IRS-1 by the reduction of ROS in liver of db/db mice is associated with the decreased phosphorylation of IRS-1 at the Ser307 residue.
###end p 42
###begin p 43
###xml 56 59 56 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink">256</sup>
###xml 274 275 274 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 268 275 268 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>C</italic></xref>
###xml 340 343 340 343 <sup xmlns:xlink="http://www.w3.org/1999/xlink">256</sup>
Finally, we examined the phosphorylation of Foxo1 at Ser256. Although no significant change in the phosphorylation level of Akt was observed in association with SOD1 overexpression, the phosphorylation of Foxo1 was significantly augumented by the SOD1 overexpression (Fig. 4C). This finding suggests that the phosphorylation of Foxo1 at Ser256 may be regulated by oxidative stress, independent of Akt activity.
###end p 43
###begin title 44
Overexpression of SOD1 reduces phosphorylation of CREB.
###end title 44
###begin p 45
###xml 89 92 89 92 <sup xmlns:xlink="http://www.w3.org/1999/xlink">133</sup>
###xml 137 139 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 176 186 176 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PGC-1&#945;</italic>
###xml 212 214 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 215 217 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 276 282 272 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5</xref>
In response to glucagon, protein kinase A phosphorylates transcription factor CREB at Ser133 and increases its transcriptional activity (23), which activates the expression of PGC-1alpha and gluconeogenic genes (16,17). Overexpression of SOD1 reduced phosphorylation of CREB (Fig. 5). This result indicates that the reduced expression of PGC-1alpha associated with reduction of ROS in liver is accompanied by reduced phosphorylation of CREB.
###end p 45
###begin title 46
###xml 40 50 40 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PGC-1&#945;</italic>
ROS induces phosphorylation of CREB and PGC-1alpha gene expression in hepatocytes.
###end title 46
###begin p 47
###xml 451 452 447 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 445 452 441 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>A</italic></xref>
###xml 613 614 605 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 607 614 599 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>B</italic></xref>
###xml 729 739 721 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PGC-1&#945;</italic>
Next, to investigate whether ROS induces the phosphorylation of CREB and, hence, results in activation of PGC1alpha in hepatocytes, we loaded ROS to a hepatocyte-derived cell line, Huh7 cells, by the addition of xanthine and xanthine oxidase, which generate superoxides. The combination of both compounds augmented CREB phosphorylation, but their effect was suppressed by BHA (a scavenger of free radicals) and MnTBAP (an SOD mimetic material) (Fig. 6A). Reflecting the changes in phosphorylation of CREB, ROS augmented PGC-1alpha expression, and this effect was blocked by pretreatment with BHA or MnTBAP (Fig. 6B). These results indicate that high ROS levels activate CREB phosphorylation and result in increased expression of PGC-1alpha.
###end p 47
###begin p 48
###xml 118 119 118 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r24">24</xref>
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 224 226 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r29">29</xref>
###xml 397 398 397 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 391 398 391 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>C</italic></xref>
###xml 438 443 438 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 457 461 457 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/m</italic>
###xml 810 811 810 811 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 804 811 804 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>D</italic></xref>
###xml 1021 1022 1021 1022 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1015 1022 1015 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>E</italic></xref>
###xml 1064 1074 1064 1070 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PGC-1&#945;</italic>
###xml 1111 1112 1107 1108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1105 1112 1101 1108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>F</italic></xref>
###xml 444 448 <span type="species:ncbi:10090">mice</span>
###xml 462 466 <span type="species:ncbi:10090">mice</span>
Previous studies showed that ROS induced phosphorylation and activation of mitogen-activated protein kinases (MAPKs) (5,24-26). In addition, ERK and p38 MAPK regulate the phosphorylation of CREB in hepatocytes and liver (27-29). Thus, we investigated the causal relationship between activation of MAPK and phosphorylation of CREB in the pathogenesis of liver insulin resistance. As shown in Fig. 6C, phosphorylation of CREB was higher in db/db mice than in db/m mice. The increased phosphorylation of CREB was restored by AdSOD1. We measured the phosphorylation state of each MAPK in the same samples. Among MAPKs, only the phosphorylation level of JNK tended to be similar to that of CREB. Next, we investigated the causal relationship between phosphorylation of JNK and CREB in Huh7 cells. As shown in Fig. 6D, ROS induced JNK phosphorylation, which was in turn counteracted by the addition of antioxidants. ROS-induced phosphorylation of CREB was also blocked by the addition of JNK-specific inhibitor SP600125 (Fig. 6E). In addition, ROS-induced activation of PGC-1alpha was counteracted by SP600125 (Fig. 6F). These results indicate that ROS-induced JNK activation is at least in part involved in the pathogenesis of hepatic insulin resistance, through the activation of CREB.
###end p 48
###begin title 49
DISCUSSION
###end title 49
###begin p 50
In this study, we investigated the role of ROS on hepatic glucose metabolism in type 2 diabetes. The major findings of the present study were that the ROS-JNK-CREB-PGC-1alpha pathway is at least in part involved in the pathogenesis of liver insulin resistance.
###end p 50
###begin p 51
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 381 386 381 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PEPCK</italic>
###xml 391 397 391 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G6Pase</italic>
###xml 399 401 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 402 404 402 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r32">32</xref>
###xml 561 566 561 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 567 571 <span type="species:ncbi:10090">mice</span>
Hyperglycemia observed in the diabetic state largely depends on increased hepatic glucose production and reduced glucose uptake in peripheral tissues. In particular, increased hepatic gluconeogenesis plays an important role in the pathophysiology of hyperglycemia (30). The regulation of gluconeogenesis predominantly depends on the expression level of gluconeogenic genes such as PEPCK and G6Pase (31,32). In the present study, overexpression of SOD1 suppressed the expression of gluconeogenic genes. The pyruvate challenge test showed that SOD1 expression in db/db mice reduced gluconeogenesis. Thus, whereas we cannot exclude the possibility that the reduction of ROS in liver altered peripheral insulin sensitivity, it is likely that the improvement in glucose level following reduction of ROS in the liver is mainly caused by reduced expression of gluconeogenic genes.
###end p 51
###begin p 52
###xml 107 108 107 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 101 108 101 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>B</italic></xref>
###xml 34 38 <span type="species:ncbi:10090">mice</span>
###xml 95 99 <span type="species:ncbi:10090">mice</span>
###xml 150 154 <span type="species:ncbi:10090">mice</span>
###xml 215 219 <span type="species:ncbi:10090">mice</span>
###xml 370 374 <span type="species:ncbi:10090">mice</span>
###xml 504 508 <span type="species:ncbi:10090">mice</span>
The body weight of AdSOD1-treated mice was higher than that of AdLacZ-treated and PBS-injected mice (Fig. 2B), although food intake of AdSOD1-treated mice was comparable with that of AdLacZ-treated and PBS-injected mice (data not shown). Accordingly, the increase in body weight was not due to the increase in appetite associated with the treatment of AdSOD1. In AdSOD1 mice, insulin sensitivity was improved and blood glucose was efficiently reduced. Accordingly, the body-weight gain in AdSOD1-treated mice might be due to the decrease of the urinary glucose excretion and the increase of glucose absorption in insulin-sensitive tissue.
###end p 52
###begin p 53
###xml 179 181 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 182 184 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 272 274 264 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 275 277 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 419 424 407 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 431 433 419 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r33">33</xref>
###xml 558 563 542 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PEPCK</italic>
###xml 568 574 552 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G6Pase</italic>
###xml 587 589 571 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r33">33</xref>
###xml 425 429 <span type="species:ncbi:10090">mice</span>
PGC-1alpha functions as a coactivator of several transcription factors that play critical roles in hepatic glucose metabolism by regulating the expression of gluconeogenic genes (16,17). The expression of PGC-1alpha is markedly increased in the liver of diabetic rodents (16,17), and inhibition of hepatic PGC-1alpha expression results in almost complete normalization of fasting glucose level and glucose tolerance in db/db mice (33). Furthermore, in nondiabetic rodents, inhibition of PGC-1alpha reduces hepatic glucose output along with downregulation of PEPCK and G6Pase expression (33). In the present study, PGC-1alpha expression was markedly suppressed by SOD1 overexpression, and this seemed to be a key molecular mechanism in the inhibition of gluconeogenesis.
###end p 53
###begin p 54
###xml 119 121 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 122 124 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r34">34</xref>
###xml 125 127 121 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r36">36</xref>
###xml 211 216 207 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 217 221 <span type="species:ncbi:10090">mice</span>
Several studies reported that insulin reduces the expression of PGC-1alpha in the liver via the inactivation of Foxo1 (18,34-36). Therefore, amelioration of glucose tolerance by reduction of ROS in the liver in db/db mice might possibly be due to an increase in insulin signaling. However, the phosphorylation level of Akt, a key signal molecule mediating the metabolic actions of insulin, was not altered by reduction of ROS.
###end p 54
###begin p 55
###xml 117 120 117 120 <sup xmlns:xlink="http://www.w3.org/1999/xlink">256</sup>
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r37">37</xref>
###xml 125 127 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r38">38</xref>
###xml 192 195 192 195 <sup xmlns:xlink="http://www.w3.org/1999/xlink">256</sup>
###xml 427 429 427 429 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 478 480 478 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r39">39</xref>
###xml 481 483 481 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r40">40</xref>
###xml 563 565 563 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r41">41</xref>
###xml 566 568 566 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r46">46</xref>
Whereas previous studies showed that Akt reduced transactivation of Foxo1 through the phosphorylation of Foxo1 at Ser256 (37,38), our data demonstrated that the phosphorylation of Foxo1 at Ser256 was augmented by reduction of ROS independently of the insulin signal at Akt phosphorylation level. Very recently, it was reported that the phosphorylation of Foxo1 is regulated by phosphatases such as protein phosphatase 2A and Ca2+-dependent protein phosphatase 2B (calcineurin) (39,40). Both protein phosphatase 2A and calcinurin are known to be activated by ROS (41-46). Therefore, the overexpression of SOD1 may augment the phosphphorylation of Foxo1 by the reduction of phosphatase activity.
###end p 55
###begin p 56
###xml 48 58 48 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PGC-1&#945;</italic>
###xml 143 153 139 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PGC-1&#945;</italic>
###xml 179 181 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 182 184 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 371 376 359 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 666 668 650 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r47">47</xref>
###xml 761 771 745 751 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PGC-1&#945;</italic>
###xml 377 381 <span type="species:ncbi:10090">mice</span>
###xml 584 589 <span type="species:ncbi:10090">mouse</span>
While Foxo1 is known as a positive regulator of PGC-1alpha, CREB, which is activated by glucagon and epinephrine, is the main regulator of the PGC-1alpha expression in the liver (16,17). In the present study, we demonstrated that downregulation of PGC-1alpha expression, elicited by reduced ROS levels in the liver, is accompanied by decreased phosphorylation of CREB in db/db mice. These results demonstrate the association of tissue ROS level and phosphorylation level of CREB. A previous study indicated that the expression level of PGC-1alpha is increased by hydrogen peroxide in mouse fibroblasts and that such an increase was mediated by CREB phosphorylation (47). In the present study, we found that ROS induced phosphorylation of CREB and activation of PGC-1alpha gene expression in Huh7 cells. Thus, ROS-induced CREB phosphorylation may be a common signal pathway in different kinds of cells. Reduction of ROS in liver is a potentially effective strategy to improve insulin resistance.
###end p 56
###begin p 57
###xml 99 100 99 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r24">24</xref>
###xml 104 106 104 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
Previous studies showed that ROS phosphorylates and activates MAPKs in both hepatocytes and liver (5,24-26) and that ERK and p38 MAPK activate CREB. We found that only the phosphorylation of JNK is associated with ROS level in liver among MAPKs. Furthermore, in Huh7 cells, activation of CREB by ROS was suppressed by the JNK inhibitor. Although the mechanism of JNK-mediated CREB phosphorylation should be elucidated, JNK at least partly mediates ROS-induced hepatic insulin resistance through the activation of CREB.
###end p 57
###begin p 58
###xml 384 387 384 387 <sup xmlns:xlink="http://www.w3.org/1999/xlink">307</sup>
###xml 514 517 514 517 <sup xmlns:xlink="http://www.w3.org/1999/xlink">307</sup>
###xml 527 528 527 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 529 531 529 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
###xml 532 534 532 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
###xml 577 579 577 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 580 582 580 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 805 807 805 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r48">48</xref>
###xml 878 883 878 883 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IRS-2</italic>
With regard to the effect of ROS on insulin signaling, we investigated tyrosine phosphorylation of IRS-1 and IRS-2. Interestingly, reduction of ROS increased tyrosine phosphorylation of IRS-1 but decreased tyrosine phosphorylation of IRS-2. With regard to the changes in expression and tyrosine phosphorylation of IRS-1, reduction of ROS attenuated phosphorylation of IRS-1 at the Ser307 residue. In the present study, reduction of ROS also attenuated JNK activation. JNK reportedly phosphorylates IRS-1 at the Ser307 residue (5,19,20) and stimulates the degradation of IRS-1 (21,22). Thus, it is likely that reduction of ROS increases the phosphorylation and expression of IRS-1 through a reduction of JNK activity. With regard to IRS-2, the gene expression is positively regulated by CREB in the liver (48). Thus, reduction of ROS in liver might reduce the gene expression of IRS-2 by attenuating CREB phosphorylation. Probably because of the opposite changes of insulin signal at IRS-1 and IRS-2, Akt phosphorylation was not affected by reduction of ROS.
###end p 58
###begin p 59
###xml 176 177 176 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 293 294 293 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 588 593 588 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 703 708 703 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 594 598 <span type="species:ncbi:10090">mice</span>
###xml 709 713 <span type="species:ncbi:10090">mice</span>
In the present study, we used overexpression of SOD1 as a strategy to reduce ROS levels in the liver. As a result of the mitochondrial and cytosolic location of SOD1 in liver (7), overexpression of SOD1 theoretically reduces both mitochondria and cytosolic superoxide. Recently, Imoto et al. (5) reported that ROS derived from mitochondria attenuate insulin signaling in cultured hepatocytes. To determine whether the effect of SOD1 on hepatic insulin resistance is different from that of SOD2 (mitochondrial isoform), we investigated the effect of overexpression of SOD2 in the liver of db/db mice using the same strategy as was used for SOD1 treatment in the present study. We found that treatment of db/db mice with AdSOD2 reduced blood glucose level and ameliorated glucose tolerance and that the effect was almost similar to overexpression of AdSOD1 (N. Kumashiro and H. Watada, unpublished observations). These results suggest that the reduction of ROS derived from mitochondria may play a key role in the improvement of insulin sensitivity.
###end p 59
###begin p 60
In conclusion, our data show that the decreased PGC-1alpha expression is at least in part involved in the amelioration of liver insulin resistance by the reduction of ROS. The present results suggest that this signal pathway is a potentially suitable therapeutic target for the treatment of type 2 diabetes.
###end p 60
###begin p 61
We thank Dr. David A. Brenner (University of North Carolina), Dr. Michael S. German (University of California San Francisco), and Dr. Ikejima Kenichi (Juntendo University) for providing the indicated materials described in the text. We also thank Naoko Daimaru and Eriko Magoshi for excellent technical assistance.
###end p 61
###begin title 62
REFERENCES
###end title 62
###begin p 63
###xml 74 79 74 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 86 87 86 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 145 146 145 146 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
###xml 179 184 179 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 320 325 319 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 348 353 347 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 358 362 357 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/m</italic>
###xml 507 508 506 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 566 571 565 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 615 620 614 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 690 691 689 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 887 891 886 890 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/m</italic>
###xml 893 894 892 893 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 900 905 899 904 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 907 908 906 907 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 929 934 928 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 936 937 935 936 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 963 968 962 967 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 970 971 969 970 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1062 1066 1061 1065 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/m</italic>
###xml 1112 1113 1109 1110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1125 1130 1122 1127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 80 84 <span type="species:ncbi:10090">mice</span>
###xml 185 189 <span type="species:ncbi:10090">mice</span>
###xml 326 330 <span type="species:ncbi:10090">mice</span>
###xml 363 367 <span type="species:ncbi:10090">mice</span>
###xml 423 428 <span type="species:ncbi:9606">human</span>
###xml 495 500 <span type="species:ncbi:10090">mouse</span>
###xml 558 562 <span type="species:ncbi:10090">mice</span>
###xml 572 576 <span type="species:ncbi:10090">mice</span>
###xml 621 625 <span type="species:ncbi:10090">mice</span>
Expression of SOD1 and quantification of ROS after injection of AdSOD1 in db/db mice. A: Seven days after intravenous injection of AdSOD1 (5 x 107 plaque-forming units each) into db/db mice, each organ was harvested and 20 mug of tissue extracts were immunoblotted with tissue extracts from the liver of AdLacZ-infected db/db mice and PBS-injected db/db and db/m mice using anti-SOD1 antibody. The 19.0-kDa band represents human SOD1 coded in AdSOD1, and the 15.9-kDa band represents endogenous mouse SOD1. B: Seven days after the injection of PBS into db/m mice or db/db mice or injection of AdLacZ or AdSOD1 into db/db mice, the amount of ROS in the liver was visualized by DHE staining. C: Quantitative analysis of nitrotyrosine in the liver at 7 days after adenovirus or PBS injection by ELISA. The acquired data by ELISA were corrected for the protein concentration in each sample (db/m, n = 4; db/db, n = 6; AdLacZ-treated db/db, n = 10; and AdSOD1-treated db/db, n = 10). The relative expression level was expressed by setting the expression level in the db/m as 1. Values are expressed as means +/- SD. *P < 0.05 vs. db/db and AdLacZ groups. (Please see  for a high-quality digital representation of this figure.)
###end p 63
###begin p 64
###xml 127 128 127 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 147 148 147 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 197 202 197 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 209 210 209 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 247 248 247 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 293 294 293 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 396 397 396 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 417 418 417 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 425 426 425 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 674 675 674 675 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 697 698 697 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 856 857 856 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 963 964 961 962 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 203 207 <span type="species:ncbi:10090">mice</span>
Effect of overexpression of AdSOD1 in liver on various metabolic parameters. Serial changes in nonfasting blood glucose level (A) and body weight (B) after injection of AdSOD1, AdLacZ, or PBS into db/db mice (n = 3 for each group). Blood glucose (C) and immunoreactive insulin concentrations (D) after intraperitoneal injection of glucose (0.5 g/kg) at 5 days after each treatment (AdLacZ group, n = 7; AdSOD1 group, n = 6). E: Blood glucose changes (% change) after intraperitoneal injection of 2 units/kg body wt of regular insulin (Humulin) at 5 days after each treatment. Values were calculated by setting the starting blood glucose concentration in each group as 100% (n = 5 for each group). F: Five days after each treatment, blood glucose concentrations were measured following intraperitoneal pyruvate injection (1.5 g/kg) after overnight fasting (n = 5 for each group) as an index of the extent of gluconeogenesis. Values are expressed as means +/- SD. *P < 0.05 vs. AdLacZ and PBS groups.
###end p 64
###begin p 65
###xml 166 171 162 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 225 226 221 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 631 632 625 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 658 659 652 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 885 886 873 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 898 903 886 891 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 172 176 <span type="species:ncbi:10090">mice</span>
###xml 274 279 <span type="species:ncbi:10090">mouse</span>
###xml 554 558 <span type="species:ncbi:10090">mice</span>
###xml 831 835 <span type="species:ncbi:10090">mice</span>
Gene expression levels of key metabolic regulators and PGC-1alpha protein expression in liver overexpressing SOD1. At 7 days after injection of AdLacZ or AdSOD1 into db/db mice, livers were collected after overnight fasting. A: Total RNA was isolated from the liver of each mouse at fasting state. The mRNA expression levels of key metabolic regulators were measured by real-time RT-PCR. Data were corrected by the expression level of TATA box-binding protein. The relative expression level was calculated by setting the expression level in the liver of mice injected with AdLacZ as 1. Values are means +/- SD of 5-6 experiments. *P < 0.05 vs. AdLacZ group. B: The liver homogenates were immunoblotted with anti-PGC-1alpha antibody. The relative expression level was calculated by setting the expression level in the liver of db/m mice as 1. Values are means +/- SD of 4 experiments. *P < 0.05 vs. db/dband AdLacZ groups.
###end p 65
###begin p 66
###xml 93 94 93 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 125 130 125 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 573 584 573 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lower panel</italic>
###xml 760 761 760 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 787 788 787 788 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 814 815 814 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 841 842 841 842 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 849 850 849 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 915 918 915 918 <sup xmlns:xlink="http://www.w3.org/1999/xlink">307</sup>
###xml 953 954 953 954 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 996 999 996 999 <sup xmlns:xlink="http://www.w3.org/1999/xlink">307</sup>
###xml 1105 1106 1105 1106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1137 1142 1137 1142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 1510 1513 1510 1513 <sup xmlns:xlink="http://www.w3.org/1999/xlink">256</sup>
###xml 1617 1618 1602 1603 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1657 1658 1642 1643 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1697 1698 1682 1683 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 131 135 <span type="species:ncbi:10090">mice</span>
###xml 1143 1147 <span type="species:ncbi:10090">mice</span>
Insulin induces phosphorylation and expression of Akt, IRS-1, IRS-2, and Foxo1 in the liver. A: At 7 days after treatment of db/db mice with AdLacZ or AdSOD1, livers were collected at 5 min after injection of 0.5 units of regular insulin through the inferior vena cava or without the injection of insulin. Whole cell extracts were applied for immunoprecipitation assay using anti-IRS-1 or anti-IRS-2 antibody. The immunoprecipitated samples were applied for Western blotting analysis using the indicated antibodies. Representative results of 3-4 experiments are shown. The lower panel showed Akt phosphorylation level in each group. Whole cell extracts from the livers were applied for the detection of insulin-induced Akt phosphorylation (AdLacZ insulin [-], n = 4; AdLacZ insulin [+], n = 7; AdSOD1 insulin [-], n = 5; AdSOD1 insulin [+], n = 7). B: Liver homogenates were immunoblotted with anti-phosphoIRS-1(Ser307) antibody or anti-IRS-1 antibody (n = 7 for each treatment). The relative Ser307 phosphorylated IRS-1 expression level was expressed by setting the mean density of blots of AdLacZ as 1. C: At 7 days after treatment of db/db mice with AdLacZ or AdSOD1, livers were collected at 5 min after injection of 0.5 units of regular insulin through the inferior vena cava or without the injection of insulin. Whole cell extracts were applied for immunoprecipitation assay using anti-Foxo1 antibody. The immunoprecipitated samples were applied for Western blotting analysis using anti-phospho-FKHR (Ser256) antibody. Representative results of 5-6 experiments are shown. Values are means +/- SD. paragraph signP < 0.05 vs. AdLacZ insulin [-] group; $P < 0.05 vs. AdSOD1 insulin [-] group; *P < 0.05 vs. corresponding AdLacZ groups.
###end p 66
###begin p 67
###xml 56 57 56 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 88 93 88 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 234 235 234 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 265 266 265 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 443 444 441 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 94 98 <span type="species:ncbi:10090">mice</span>
###xml 385 389 <span type="species:ncbi:10090">mice</span>
Effects of SOD1 overexpression on CREB phosphorylation. A: At 7 days after treatment of db/db mice with AdLacZ or AdSOD1, livers were collected after overnight fasting. The liver homogenates were immunoblotted with anti-phospho-CREB (p-CREB) or anti-CREB antibody (n = 8 for each treatment). The relative expression level was calculated by setting the expression level in the liver of mice injected with AdLacZ as 1. Values are means +/- SD. *P < 0.05 vs. AdLacZ group.
###end p 67
###begin p 68
###xml 37 47 37 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PGC-1&#945;</italic>
###xml 79 80 75 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 473 474 466 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 682 692 674 680 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PGC-1&#945;</italic>
###xml 739 740 725 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 810 811 784 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 867 868 841 842 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 965 970 939 944 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 1294 1295 1266 1267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1307 1312 1279 1284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 1332 1333 1304 1305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1663 1664 1632 1633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1906 1907 1875 1876 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 2103 2113 2071 2077 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PGC-1&#945;</italic>
###xml 2236 2237 2197 2198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2307 2308 2256 2257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 926 930 <span type="species:ncbi:10090">mice</span>
###xml 971 975 <span type="species:ncbi:10090">mice</span>
###xml 1257 1261 <span type="species:ncbi:10090">mice</span>
ROS induces CREB phosphorylation and PGC-1alpha gene expression in Huh7 cells. A: After overnight starvation, Huh7 cells were treated with 400 mumol/l xanthine (XA) and 40 mU/ml xanthine oxidase (XO). The cell extracts were then applied for Western blotting to detect CREB phosphorylation. When antioxidants were used, 400 mumol/l BHA or 400 mumol/l MnTBAP was added to the medium 20 min before treatment with XA and XO. Representative results of 4 experiments were shown. B: After overnight starvation, Huh7 cells were treated with 400 mumol/l XA and 40 mU/ml XO for 180 min. Total RNA extracted from each cell was then applied for real-time RT-PCR to quantitate the expression of PGC-1alpha. Values are means +/- SD of 4-5 experiments. #P < 0.05 vs. pretreatment (-) before XA and XO treatment. double daggerP < 0.05 vs. pretreatment (-) after XA and XO treatment. C: Seven days after intravenous injection of PBS into db/m mice or of PBS, AdLacZ, or AdSOD1 into db/db mice, liver was harvested and applied for immunoblotting with the corresponding antibody. Data represent the amounts of phosphorylated protein divided by the amount of the respective protein. The relative expression level was calculated by setting the expression level in liver of db/m mice as 1. Values are means +/- SD. *P < 0.05 vs. db/db and AdLacZ groups. D: After overnight starvation, Huh7 cells were treated with 400 mumol/l XA and 40 mU/ml XO. The phosphorylation of JNK was assessed at 15 and 60 min after treatment. The antioxidant (BHA 400 mumol/l or MnTBAP 400 mumol/l) was added at 20 min before the addition of XA and XO. Representative results of four experiments were shown. E: Thirty micromolars of SP600125, a JNK-specific inhibitor, were pretreated instead of antioxidants. The phosphorylation of CREB and JNK were then assessed at 15 and 60 min after treatment. Representative results of 4 experiments were shown. F: After overnight starvation, Huh7 cells were treated with 400 mumol/l XA and 40 mU/ml XO. Total RNA extracted from each cell was then applied for real-time RT-PCR to quantitate the expression of PGC-1alpha. Thirty mumol/l SP600125 were added 20 min before the addition of XA and XO. Values are means +/- SD of 4-5 experiments. #P < 0.05 vs. pretreatment (-) before XA and XO treatment. double daggerP < 0.05 vs. pretreatment (-) after XA and XO treatment for 180 min.
###end p 68

